Lactoferrin 관련 Recurrent Infections

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg vs: Placebo Outcome: Disease remission 효과: None None

대상 집단: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None vs: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus 효과: None None

대상 집단: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None vs: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease 효과: Decreased defensin and LL-37 in Crohn's patients None

대상 집단: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None vs: None Outcome: immune function 효과: None None

대상 집단: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg vs: baseline Outcome: oxidative stress markers 효과: or 2 None

대상 집단: general population

Key Statistics

연구

2000

참여자

↑

Positive

등급

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 인용

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 인용

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 인용

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 인용

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 인용

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 인용

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 인용

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

상한량: No established UL; well-tolerated up to 1,200 mg/day

연구에서 사용된 용량

용량	기간	효과	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

권장 복용 시간: On empty stomach

Safety & Side Effects

보고된 부작용

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

알려진 상호작용

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

일일 최대 섭취 허용량: No established UL; well-tolerated up to 1,200 mg/day

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

한눈에 보기

Evidence Strength92%

High confidence

연구 분석

RCT (1)Meta (0)Other (7)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: Recurrent Infections

자세히 알아보기

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.